KR20220098168A - 간 장애의 치료 - Google Patents

간 장애의 치료 Download PDF

Info

Publication number
KR20220098168A
KR20220098168A KR1020227018657A KR20227018657A KR20220098168A KR 20220098168 A KR20220098168 A KR 20220098168A KR 1020227018657 A KR1020227018657 A KR 1020227018657A KR 20227018657 A KR20227018657 A KR 20227018657A KR 20220098168 A KR20220098168 A KR 20220098168A
Authority
KR
South Korea
Prior art keywords
compound
patient
liver
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227018657A
Other languages
English (en)
Korean (ko)
Inventor
마르티즌 페노
유진 왕
웨이동 종
케빈 클루처
Original Assignee
테른스 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테른스 파마슈티칼스, 인크. filed Critical 테른스 파마슈티칼스, 인크.
Publication of KR20220098168A publication Critical patent/KR20220098168A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227018657A 2019-11-08 2020-11-06 간 장애의 치료 Withdrawn KR20220098168A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US62/933,277 2019-11-08
US202063004403P 2020-04-02 2020-04-02
US63/004,403 2020-04-02
PCT/US2020/059522 WO2021092474A1 (en) 2019-11-08 2020-11-06 Treating liver disorders

Publications (1)

Publication Number Publication Date
KR20220098168A true KR20220098168A (ko) 2022-07-11

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018657A Withdrawn KR20220098168A (ko) 2019-11-08 2020-11-06 간 장애의 치료

Country Status (11)

Country Link
EP (1) EP4054567A4 (enExample)
JP (1) JP2023501386A (enExample)
KR (1) KR20220098168A (enExample)
CN (1) CN114667142A (enExample)
AU (1) AU2020380968A1 (enExample)
BR (1) BR112022008639A2 (enExample)
CA (1) CA3160445A1 (enExample)
CL (1) CL2022001167A1 (enExample)
IL (1) IL292459A (enExample)
MX (1) MX2022005407A (enExample)
WO (1) WO2021092474A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259279A1 (en) 2020-12-14 2023-10-18 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
TW202539702A (zh) * 2024-03-08 2025-10-16 大陸商上海拓界生物醫藥科技有限公司 靶向ＩＮＨＢＥ的ＲＮＡｉ劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
MX2018011813A (es) * 2016-03-28 2019-01-24 Intercept Pharmaceuticals Inc Medicina obtenida mediante la combinacion de agonista fxr y arb.
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20210121493A1 (en) * 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
EP3844156A4 (en) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISEASES

Also Published As

Publication number Publication date
CN114667142A (zh) 2022-06-24
MX2022005407A (es) 2022-05-24
CL2022001167A1 (es) 2023-02-10
BR112022008639A2 (pt) 2022-07-19
WO2021092474A1 (en) 2021-05-14
IL292459A (en) 2022-06-01
CA3160445A1 (en) 2021-05-14
EP4054567A4 (en) 2024-01-10
EP4054567A1 (en) 2022-09-14
AU2020380968A1 (en) 2022-05-12
JP2023501386A (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
US20240316025A1 (en) Combination treatment of liver disorders
US20210379040A1 (en) Combination treatment of liver disorders
US20230241071A1 (en) Combination treatment of liver disorders
Davis Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics
EP3743064B1 (en) Treatment of proteinuria
CA3160445A1 (en) Treating liver disorders
EP4166137B1 (en) Therapeutic agent for fatty liver disease
KR101057485B1 (ko) 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
US20220387414A1 (en) Treating liver disorders
Evasio et al. Effect of nolomirole on monocrotaline-induced heart failure
HK40069155A (en) Treatment of proteinuria
HK40031619B (en) Treatment of proteinuria
Haddley Lu-AA-21004

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220602

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20250102

WITB Written withdrawal of application